Search 

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

Northern Biotechnologies has raised $1.5M in round "a" private funding. Northern is seeking commercialization and investment partnerships to continue the development of additional anti-bacterial, anti- viral and anti-fungal applications of our technology which require additional testing, proof of concept and commercialization partners.

Northern Biotechnologies is pioneering the commercialization of an innovative, long lasting, therapeutic anti-microbial technology that has significant applications in the Human Health Care arena. Infectious disease control and prevention

can be revolutionized by integration of our cost saving technology. Issued Patents and proprietary production IP offer a stable platform for growth and partnership into all human related applications of the technology. A unique feature of the technology is its extended protection of 1-3 days through each application. Additionally, the physical method of pathogen destruction prevents formation of resistant strain types, in contrast to existing technologies that rely on metabolic action for kill. Testing shows high performance anti-bacterial, anti-fungal and anti- viral functioning in various direct, topical, and wound care, nasal/ oral and related dosing mechanisms of the technology. We are in process with the first New Drug Application for antiseptic hand wash, and are looking for partners to pursue additional drug approvals in specific markets.

Existing product branding in the Human market is Prefense hand sanitizer and wipes. In addition to human applications, Northern holds over twenty-five global patents for anti-microbial water filtration using our technology. We also hold EPA registrations for persistent antimicrobial filter media. Significant opportunity exists in the technology used as a multi surface sanitizer for all levels of food production. Other existing product lines and cash flow are in place from additional internally developed technologies including high performance filtration medias, biotech remediation and process technologies used in petroleum, agricultural, and industrial processing. Northern also holds nationally placed consumer and professional brand lines of "green probiotic" cleaning products based on our IP and manufacturing base. Additionally, our cGMP contract packaging division sells our proprietary formulations to many national brands in a variety of markets. Company management is made of a diverse team with the experience and drive required to steer strong growth and relationships with partner companies.